Advances in antiplatelet therapy for acute coronary syndromes
- Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, Oxfordshire, UK
- Correspondence to Dr Hussain Contractor, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford, Oxfordshire OX3 9DU, UK;
Contributors Both HC and NR had the original idea for this review article. NR devised the structure of the article. Both HC and NR searched the literature and collected data. HC wrote the first draft of the manuscript, which was then revised several times by both HC and NR. HC completed the final draft before original submission.
- Received 24 October 2011
- Accepted 31 January 2012
- Published Online First 22 February 2012
Admissions to emergency care centres with acute coronary syndromes remain one of the principal burdens on healthcare systems in the Western world. Early pharmacological treatment in these patients is crucial, lessening the impact on both morbidity and mortality, with the cornerstone of management being antiplatelet agents. While aspirin and clopidogrel have been the drugs of choice for nearly a decade, an array of newer, more potent antiplatelet agents are now available or in late stage development. Data are rapidly gathering suggesting these agents have superior anti-ischaemic properties, improving patient outcomes, but that for some agents increased vigilance and appropriate patient selection may be necessary to guard against bleeding complications. In this review, the authors aim to deliver an overview of the changing field of antiplatelet therapy and provide information about the relative risks and benefits of these newer agents, many of which will be entering widespread clinical use imminently.
- Acute coronary syndromes
- ischaemic heart disease
- platelet inhibition
- adult cardiology
- coronary heart disease
- coronary intervention
- myocardial infarction
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.